Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic value of total, free and lipoprotein fraction-bound plasma mitotane levels in advanced adrenocortical carcinoma: a prospective study of the ENDOCAN-COMETE-Cancer network.
Faron M, Naman A, Delahousse J, Hescot S, Hadoux J, Castinetti F, Drui D, Renoult-Pierre P, Libe R, Lamartina L, Leboulleux S, Al-Ghuzlan A, Lombès M, Paci A, Baudin E; For Endocan-Comete Network. Faron M, et al. Among authors: hescot s. J Endocrinol Invest. 2024 Aug 22. doi: 10.1007/s40618-024-02439-7. Online ahead of print. J Endocrinol Invest. 2024. PMID: 39172357
Childhood pancreatic neuroendocrine neoplasms: A national experience.
Courtel T, Orbach D, Lacour B, Roumy M, Hescot S, Desandes E, Philippe-Chomette P, Sarnacki S, Irtan S, Dijoud F, Kubicek P, Brisse H, Fresneau B, Pire A, Réguerre Y, Mallebranche C. Courtel T, et al. Among authors: hescot s. Pediatr Blood Cancer. 2025 Feb;72(2):e31258. doi: 10.1002/pbc.31258. Epub 2024 Aug 12. Pediatr Blood Cancer. 2025. PMID: 39135330
Survival of patients managed in France for duodenal neuroendocrine tumors (D-NET): a 20-year multicenter cohort study from the GTE group: a cohort study.
Mekkan-Bouv Hez M, Derbey L, de Mestier L, Lorenzo D, Walter T, Perrier M, Cadiot G, Goichot B, Pracht M, Lièvre A, Coriat R, Valancot S, Guimbaud R, Carrere N, Bacoeur-Ouzillou O, Belleannée G, Smith D, Laboureau S, Hescot S, Julie C, Teissier MP, Thereaux J, Ferru A, Evrard C, Mathonnet M, Christou N. Mekkan-Bouv Hez M, et al. Among authors: hescot s. Int J Surg. 2024 Jul 1;110(7):4259-4265. doi: 10.1097/JS9.0000000000001382. Int J Surg. 2024. PMID: 38573078 Free PMC article.
Tumor mutational burden assessment and standardized bioinformatics approach using custom NGS panels in clinical routine.
Dupain C, Gutman T, Girard E, Kamoun C, Marret G, Castel-Ajgal Z, Sablin MP, Neuzillet C, Borcoman E, Hescot S, Callens C, Trabelsi-Grati O, Melaabi S, Vibert R, Antonio S, Franck C, Galut M, Guillou I, Halladjian M, Allory Y, Cyrta J, Romejon J, Frouin E, Stoppa-Lyonnet D, Wong J, Le Tourneau C, Bièche I, Servant N, Kamal M, Masliah-Planchon J. Dupain C, et al. Among authors: hescot s. BMC Biol. 2024 Feb 20;22(1):43. doi: 10.1186/s12915-024-01839-8. BMC Biol. 2024. PMID: 38378561 Free PMC article.
[18F]FDG PET/CT for predicting triple-negative breast cancer outcomes after neoadjuvant chemotherapy with or without pembrolizumab.
Seban RD, Arnaud E, Loirat D, Cabel L, Cottu P, Djerroudi L, Hescot S, Loap P, Bonneau C, Bidard FC, Huchet V, Jehanno N, Berenbaum A, Champion L, Buvat I. Seban RD, et al. Among authors: hescot s. Eur J Nucl Med Mol Imaging. 2023 Nov;50(13):4024-4035. doi: 10.1007/s00259-023-06394-y. Epub 2023 Aug 22. Eur J Nucl Med Mol Imaging. 2023. PMID: 37606858
Outcome of adrenocortical carcinoma patients included in early phase clinical trials: Results from the French network ENDOCAN-COMETE.
Hescot S, Debien V, Hadoux J, Drui D, Haissaguerre M, de la Fouchardiere C, Vezzosi D, Do Cao C, Libé R, Le Tourneau C, Baudin E, Massard C, du Rusquec P; from the French ENDOCAN-COMETE network. Hescot S, et al. Eur J Cancer. 2023 Aug;189:112917. doi: 10.1016/j.ejca.2023.05.006. Epub 2023 May 16. Eur J Cancer. 2023. PMID: 37277263 Clinical Trial.
Prognostic of recurrence and survival in poorly differentiated thyroid cancer.
Hescot S, Al Ghuzlan A, Henry T, Sheikh-Alard H, Lamartina L, Borget I, Hadoux J, Baudin E, Dupuy C, Nikitski AV, Nikiforov YE, Schlumberger M, Nikiforova MN, Leboulleux S. Hescot S, et al. Endocr Relat Cancer. 2022 Sep 30;29(11):625-634. doi: 10.1530/ERC-22-0151. Print 2022 Nov 1. Endocr Relat Cancer. 2022. PMID: 36040800
55 results